

Inited States Patent and Trademark Office

ser 1,

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NUMBER

FILING OR 371 (c) DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER


10/725,484

12/03/2003

Ramon A. Torres

TORRES=1B

001444 BROWDY AND NEIMARK, P.L.L.C. 624 NINTH STREET, NW SUITE 300 WASHINGTON, DC 20001-5303



**CONFIRMATION NO. 3990** 

FORMALITIES LETTER

\*OC00000013488277\*

Date Mailed: 08/09/2004

# NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Filing Date Granted

SEQ -090(2004.

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Replies should be mailed to:

Mail Stop Missing Parts

Commissioner for Patents

P.O. Box 1450

## Alexandria VA 22313-1450

A copy of this notice <u>MUST</u> be returned with the reply.

Initial Patent Examination Division (703) 308-1202
PART 1 - ATTORNEY/APPLICANT COPY



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Atty. Docket: TORRES=1E
Ramon A. TORRES	Examiner:
Appln. No.: 10/725,484	Washington, D.C.
Filed: December 3, 2003	September 28, 2004
For: TREATMENT OF HIV-ASSOCIATED)  DYSMORPHIAL DYSMORPHIAL	Confirmation No.: 3990

#### RESPONSE TO SEQUENCE LISTING REQUIREMENT

Honorable Commissioner for Patents U.S. Patent and Trademark Office 2011 South Clark Place Customer Window, Mail Stop Sequence Crystal Plaza Two, Lobby, Room 1B03 Arlington, Virginia 22202

#### Sir:

Responsive to the Notice to Comply with Sequence
Listing Rules included in the Notification of Missing
Requirements dated August 9, 2004, applicants state as
follows:

Upon a careful review of the application as filed, applicants have determined that the text of the application contains many acronyms but does not contain any sequences with at least 4 amino acids or 10 nucleotides. Consequently, the sequence rules do not apply in this matter, and applicants are proceeding in reliance thereof. In the event that the USPTO has identified sequence disclosures in the instant application

In re of Appln. No. 10/725,484

that require a sequence identifier and presentation in a sequence listing section, the USPTO is respectfully invited to point out the identified sequence disclosures to the applicants.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C. Attorneys for Applicant(s)

Ву

ALLEN C. YUN

Registration No. 37,971

ACY:pp

Telephone No.: (202) 628-5197 Facsimile No.: (202) 737-3528 G:\BM\S\Ser\\torresIB\pto\Response to notice to comply (SEQ).doc